Catheter Ablation for Atrial Fibrillation - 09/06/12

Doi : 10.1016/j.hlc.2012.03.122

Stuart P. Thomas, PhD, FCSANZ ^a,^⁎ , Prashanthan Sanders, PhD, FCSANZ ^b
^a Department of Cardiology, Westmead Hospital, University of Sydney and Macquarie University, Australia
^b Centre for Heart Rhythm Disorders (CHRD), Royal Adelaide Hospital and University of Adelaide, Adelaide, Australia

Corresponding author at: Department of Cardiology, Westmead Hospital, Westmead 2145, Australia. Tel.: +61 2 9845 6795; fax: +61 2 9845 8323.

Résumé

Atrial fibrillation (AF) is the most common clinically important cardiac arrhythmia. It is an important cause of stroke, contributes to the burden of heart failure and is a major contributor to health expenditure. Percutaneous catheter ablation is superior to medical therapy in reducing AF recurrences. It has an important role in treatment of patients with failed drug therapy. Successful catheter ablation improves left ventricular function in patients with heart failure. In addition, it may be appropriate for selected highly symptomatic patients as first line therapy. Catheter ablation for AF has been shown in randomised trials to reduce hospital admissions and improve quality of life. There is evidence from registry data to suggest it reduces the risk of stroke and improves mortality. Cost effectiveness has been demonstrated by modelling studies in both Europe and the United States.

Le texte complet de cet article est disponible en PDF.

Keywords : Atrial fibrillation, Catheter ablation, Pulmonary veins, Pulmonary vein isolation, Cost effectiveness, Stroke